Trial Profile
Phase 1b, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of QR-010 in Subjects With Homozygous ΔF508 Cystic Fibrosis
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Eluforsen (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; First in man
- Sponsors ProQR Therapeutics
- 15 Jan 2019 Status changed from active, no longer recruiting to completed.
- 25 Sep 2017 According to a ProQR Therapeutics media release, data from the trial will be presented at the North American CF Conference (NACFC) on November 2-4, 2017.
- 25 Sep 2017 Topline results from phase Ib part of the trial published in a ProQR Therapeutics media release.